STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Biofrontera Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Biofrontera AG and related Reporting Persons disclosed substantial potential ownership of Biofrontera Inc. common stock through conversion rights in Series D Convertible Preferred Stock. BFAG holds 3,019 shares of Series D Preferred Stock convertible, subject to a conversion cap, into up to 4,831,172 common shares but limited by a Maximum Percentage of 19.99%, which currently yields beneficial ownership of 2,493,346 shares (19.54%). Collectively certain Reporting Persons report beneficial ownership of 2,552,230 shares (19.99%). The Series D conversion follows a September 16, 2025 stockholder approval; conversion economics equal $1,000 divided by $0.6249 per share prior to rounding. The Agreement transferring U.S. rights to Ameluz and RhodoLED includes a royalty structure of 12% if U.S. Ameluz revenue is under $65.0 million and 15% if above that threshold. Reporting Persons disclaim formation of a group while acknowledging interlocking ownership and governance relationships.

Positive
  • Clear disclosure of convertible Series D Preferred conversion mechanics and resulting maximum common shares
  • Defined conversion cap (Maximum Percentage of 19.99%) that limits immediate dilution to other holders
  • Board appointment right for BFAG while it holds Series D Preferred Stock, linking economic interest to governance
  • Royalty terms disclosed for U.S. Ameluz sales (12% under $65.0M; 15% above $65.0M), which clarify revenue-sharing from the U.S. business
Negative
  • Potential dilution from conversion could materially increase outstanding shares if the Maximum Percentage is raised
  • Pending litigation in Germany challenging IPO-related approvals, which remains unresolved and may affect related parties
  • Concentrated ownership and interlocking roles among Reporting Persons could raise governance and control concerns despite disclaimers of a group

Insights

TL;DR: Convertible preferred gives BFAG material potential equity stake (~19.5%) and contingent dilution; conversion limits and royalty terms are material to valuation.

BFAG's 3,019 Series D preferred shares convert at a fixed economic ratio producing up to 4.83 million common shares, but a contractual cap currently limits conversion to produce 2,093,346 common shares, yielding BFAG beneficial ownership of 2,493,346 shares (19.54%). The filing quantifies ownership percentages precisely and discloses the royalty schedule for U.S. Ameluz revenue, which affects future cash flows tied to the U.S. business. The position and conversion mechanics are material to outstanding share count and potential dilution scenarios; investors should note the specified conversion cap and the explicit mechanics for increasing that cap.

TL;DR: Reporting Persons reveal significant governance links and board appointment rights, but they disclaim a formal group.

The Agreement grants BFAG the right to appoint one director if the issuer's board has up to seven members (two if eight or more), a governance consequence that accompanies the economic stake. The filing details overlapping management and supervisory roles among reporting entities and individuals and discloses a pending German litigation concerning the IPO approvals. While these relationships create potential influence, the reporting parties expressly disclaim forming a group under Section 13(d)(3), and several parties similarly disclaim beneficial ownership beyond contractual limits.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Biofrontera AG
Signature:/s/ Maria del Pilar de la Huerta Martinez
Name/Title:Maria del Pilar de la Huerta Martinez/Chief Financial Officer
Date:09/19/2025
Deutsche Balaton Aktiengesellschaft
Signature:/s/ Rolf Birkert
Name/Title:Rolf Birkert
Date:09/19/2025
VV Beteiligungen Aktiengesellschaft
Signature:/s/ Wilhelm Konrad Thomas Zours
Name/Title:Wilhelm Konrad Thomas Zours
Date:09/19/2025
Signature:/s/ Alexander Link
Name/Title:Alexander Link
Date:09/19/2025
Delphi Unternehmensberatung Aktiengesellschaft
Signature:/s/ Wilhelm Konrad Thomas Zours
Name/Title:Wilhelm Konrad Thomas Zours
Date:09/19/2025
Wilhelm Konrad Thomas Zours
Signature:/s/ Wilhelm Konrad Thomas Zours
Name/Title:Wilhelm Konrad Thomas Zours
Date:09/19/2025
Alexander Link
Signature:/s/ Alexander Link
Name/Title:Alexander Link
Date:09/19/2025
Hansjoerg Plaggemars
Signature:/s/ Hansjoerg Plaggemars
Name/Title:Hansjoerg Plaggemars
Date:09/19/2025
Maria del Pilar de la Huerta Martinez
Signature:/s/ Maria del Pilar de la Huerta Martinez
Name/Title:Maria del Pilar de la Huerta Martinez
Date:09/19/2025

FAQ

What percentage of Biofrontera Inc. (BFRIW) does BFAG currently beneficially own?

BFAG beneficially owns 2,493,346 shares, representing 19.54% of the class on the filing's basis.

How many common shares can BFAG convert its Series D Preferred Stock into?

BFAG's 3,019 Series D Preferred shares are convertible into up to 4,831,172 common shares in total, but conversion is currently limited by the 19.99% cap to a maximum of 2,093,346 convertible shares.

What are the royalty terms disclosed related to Ameluz U.S. rights?

The Agreement provides a 12% royalty when U.S. Ameluz revenue is under $65.0 million and 15% when U.S. Ameluz revenue exceeds $65.0 million.

Do the Reporting Persons claim to be a group under Section 13(d)?

No. The Reporting Persons state they may be deemed a group but expressly disclaim the existence of any such group.

Are there any legal proceedings disclosed in the filing?

Yes. Deutsche Balaton filed litigation in Cologne challenging BFAG board resolutions related to the issuer's IPO; the matter is pending at the Federal Supreme Court.
Biofrontera

NASDAQ:BFRIW

BFRIW Rankings

BFRIW Latest News

BFRIW Latest SEC Filings

BFRIW Stock Data

1.49M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
WOBURN